NUCANA PLC-ADR (NCNA)
US67022C2052 - ADR
NUCANA PLC-ADR
NASDAQ:NCNA (11/4/2024, 8:25:53 PM)
After market: 1.61 +0.06 (+3.87%)1.55
+0.01 (+0.65%)
Company Profile
NuCana PLC is a GB-based company operating in Biotechnology industry. NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The firm is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Company Info
NUCANA PLC-ADR
Lochside House, 3 Lochside Way
Edinburgh EH12 9DT
P: 4401313571111
CEO: Hugh Griffith
Employees: 27
Website: https://www.nucana.com/
NCNA News
a month ago - NuCana plcNuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United Statesa month ago - NuCana plcNuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United StatesEDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States...
2 months ago - Yahoo FinanceNuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock SurgesOn Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) for metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. In this 12-patient cohort, most patients had received at least two prior lines of PD-1 inhibitor therapy. Nine out of twelve (75%) achieved disease control, including two patients who achieved Partial Resp
2 months ago - NuCana plcNuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile
2 months ago - NuCana plcNuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses,...
2 months ago - NuCana plcNuCana Announces Update for Phase 2 Randomized Colorectal Cancer StudyNCNA Twits
Here you can normally see the latest stock twits on NCNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
